研报掘金丨华鑫证券:首予瑞迈特“买入”评级,业绩有望持续增长

格隆汇
30 Jun

华鑫证券研报指出,瑞迈特业绩符合预期,打造全球呼吸机一体化龙头。公司2023、2024、2025Q1的毛利率分别为46.14%、48.34%、49.57%,呈现稳步提升的态势。公司耗材业务国际化布局持续深耕,美国市场,公司通过RH公司组建的专业耗材团队积极开展市场推广,并通过在睡眠监测机构每月免费发放面罩的策略,提升品牌影响力和市场认知度。欧洲市场,公司于2023年成立法国数据型子公司,覆盖欧洲市场,通过解决医保报销问题和完善基础设施吸引更多代理商合作,进一步拓展了市场规模。另外,公司深耕呼吸健康领域医疗设备与耗材,持续布局全球市场,产品力、品牌力及全球竞争力稳步提升。公司呼吸机及耗材市场地位领先,随着海外市场布局的持续推进,业绩有望持续增长,首次覆盖,给予“买入”投资评级。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10